TJE, T., A, D., S, S., & M, L. (2021). Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press.
Chicago Style (17th ed.) CitationTJE, Tarigan, Dwijayanti A, Setyowati S, and Louisa M. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.
MLA (8th ed.) CitationTJE, Tarigan, et al. Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin Versus Originator Insulin Glargine in Patients with Type 2 Diabetes. Dove Medical Press, 2021.
Warning: These citations may not always be 100% accurate.